VIBATIV Website References:
VIBATIV Website References:
1. VIBATIV [Package Insert]. Nashville, TN: Cumberland Pharmaceuticals Inc.; December 2020.
2. Duncan LR, et al. Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017). Microb Drug Resist. 2020; 26(8): 934-943.
3. Duncan LR, et al. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. J Glob Antimicrob Resist. 2020; 20: 118–123.
4. Sweeney D, et al. Evaluation of the bactericidal activity of telavancin against Staphylococcus aureus using revised testing guideline. Diagn Microbiol and Infect Dis. 2017; 89: 83-85.
5. Gotfried MH, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008; 52: 92-97.
6. Sun HK, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006; 50(2): 788-790.
7. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.
8. Leadbetter MR, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot. 2004; 57: 326-336.
9. Chan C, et al. A review of telavancin activity in in-vitro biofilms and animal models of biofilm-associated infections. Future Microbiol. 2015; 10(8): 1325–1338.
10. Hedge SS, Janc JW. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection. Expert Rev Anti Infect Ther. 2014; 12(12): 1463-1475.
11. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009; 53(8): 3375-3383.
12. Rubinstein E, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis. 2011; 52(1): 31-40.
13. Barriere BL, et al. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010; 5(12): 1765-1773.
14. Stevens DL, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: Update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(2): 147-159.
15. Bressler AM, et al. Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR). Drugs Real World Outcomes. 2019; 6(4): 183-191.
16. Sand P, et al. Chemical Stability of Telavancin in Elastomeric Pumps. Curr Ther Res Clin Exp. 2015; 77: 99–104.
17. Mendes RE, Farrell DJ, Sader HS, Jones RN. Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying a revised susceptibility testing method. 114th General Meeting of the American Society for Microbiology (ASM); May 17-20, 2014; Boston, MA. Poster 1.
18. Smith JR, et al. Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and one-Compartment Pharmacokinetic/Pharmacodynamic Models. Antimicrob. Agents and Chemo. 2015; 59(9): 5529-5534.
19. Niederman M, et al. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infection Dis Ther. 2019; 8(3): 445 – 452.
20. Stryjewski ME, et al. Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms. Clinical Infectious Disease. 2008; 46:1683 – 93